Anticonvulsant effect of 5-ethyl,5-phenyl,2-pyrrolidinone and its possible relationship to gamma-aminobutyric acid-dependent inhibitory mechanisms.
D000613:Aminobutyrates / Q000502:physiology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D018691:Excitatory Amino Acid Antagonists; D006835:Hydrazones / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D010672:Phenytoin / Q000494:pharmacology; D011732:Pyridoxal Phosphate / Q000037:antagonists & inhibitors; D011760:Pyrrolidinones / Q000494:pharmacology*; D012018:Reflex / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced; D012890:Sleep / Q000187:drug effects; D013331:Strychnine / Q000037:antagonists & inhibitors; D013882:Thiosemicarbazones / Q000037:antagonists & inhibitors; D013997:Time Factors
D000613:Aminobutyrates; D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D018691:Excitatory Amino Acid Antagonists; D006835:Hydrazones; D011760:Pyrrolidinones; D013882:Thiosemicarbazones; D011732:Pyridoxal Phosphate; D010672:Phenytoin; D013331:Strychnine; D010433:Pentylenetetrazole